Anti-aggregatory Effect of Anti-platelet Agents.
- Author:
Joon Shik MOON
1
;
Byung In LEE
;
Woo Gyung KIM
;
Jim Soo KIM
;
Kir Young KIM
;
Hyun Sook KIM
;
Byung Chul LEE
Author Information
1. Department of Neurology, Yonsei University, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- MeSH:
Adenosine;
Adenosine Diphosphate;
Ants;
Aspirin;
Blood Platelets;
Collagen;
Epinephrine;
Humans;
Neurology;
Platelet Activating Factor;
Platelet Aggregation;
Platelet-Rich Plasma;
Prescriptions;
Prospective Studies;
Stroke;
Ticlopidine;
Trapidil
- From:Journal of the Korean Neurological Association
1991;9(3):286-296
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We investigated a prospective study to compare the effects of single or combined use of three commonly used anti-platelet agents; aspirin, ticlopidine and trapidil, on the platelet aggregation. Total 78 patients admitted to the neurology ward of Yonsei University Hospital with acute ischemic stroke were randomly divided into 7 groups .The blood was drawn from these patients before and a week after the prescription of anti-platelet agents pertinent to each group. Platelet aggregation was measured by using a platelet aggregometer (Chrono-Log Lumi Aggregometer Model 400) after addition o f adenosine diphosphite (ADP), collagen, epinephrine, ant platelet activating factor (PAF) on the platelet rich plasma. The results showed that 1) trapidil most effectively inhibited platelet aggregation by PAF, 2) aspirin and/or ticlopidine were superior to trapidil for the inhibitory effect on platelet aggregation by ADP. Collagen and epinephrine. 3) all three drug combination therapy successfully inhibited platelet aggregation by ADP. Collagen, epinephrine and PAF. Therefore. This in-vitro study suggests that combined use of anti-platelet agents having different mechanisms may provide more effective anti-platelet act;ons in acute ischemic stroke patients.
